- Price Zscore is at a recent 2 week high. A recent high ZScore means price movement is accelerating at a record speed.
- Volatility is at a recent 2 week high. A high volatility of stock movement indicates uncertainty.
- RSI is at a high level of 80. A high level of RSI indicates the stock is overbought.
- MACD is crossing MACD signal line at 0.7. MACD crossing signal line is bullish signal.
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes fromFinra
Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Merck stock recovered from a dip Monday after the company scrapped development of two coronavirus vaccines the company said were inferior to already authorized drugs by other pharma players.
Johnson & Johnson is expected soon to release test results for its coronavirus vaccine in a move that could rock vaccine stocks Pfizer and Moderna. Pfizer and Moderna have authorized drugs.
Key indexes closed mixed Monday, as the Nasdaq hit a fresh closing high and the Dow Jones Industrial Average trimmed most of a 432-point loss.
After Moderna and Merck’s news, the path for a swift vaccine rollout looks a bit rockier than it did last week.
Yahoo Finance’s Alexis Christoforous and JR Rahn, MindMed Co-CEO discuss growth amid the pandemic and a new ETF for psychedelics.
Shares of Humanigen Inc. were down 2.5% in trading on Monday after it announced a contract development and manufacturing deal with Emergent BioSolutions Inc. for its experimental COVID-19 treatment. Emergent's stock was down 1.7%. The investigational therapy, lenzilumab, is currently being tested in a Phase 3 trial in hospitalized COVID-19 patients. Humanigen said it plans to file for emergency use authorization in the first quarter of this year. Emergent has signed a number of deals to manufact...
Shares of Johnson & Johnson were up 0.9% in trading on Monday, as the company nears the anticipated disclosure of interim results from a late-stage clinical trial evaluating its single-dose COVID-19 vaccine candidate. J&J said in mid-December it expects to share findings from the Phase 3 trial by the end of January, which would it the third company testing coronavirus vaccines in the U.S. to announce results from a closely watched Phase 3 trial. The other two vaccines, developed by BioNTech SE /...
Dr. Shereef Elnahal — CEO of University Hospital and former NJ DOH Commissioner — joins Yahoo Finance Live to discuss the latest developments on the coronavirus vaccination front, and what the government needs to do on a federal level to get communities of color to trust the medical establishment to boost inoculation.
Moderna announces new vaccine studies for virus strains as Merck drops out of the race.
Johnson & Johnson (NYSE:JNJ) releases its next round of earnings this Tuesday, January 26. Get the latest predictions in Benzinga's essential guide to the company's Q4 earnings report.What Are Earnings, Net Income, And Earnings Per Share? Earnings and especially earnings per share (EPS) are useful measures of a company's profitability. Total earnings, which is also referred to as net income, equals total revenue minus total expenses. EPS equals to net income divided by the number of shares outst...